Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 5/20 | 0.32 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21876170 | 1.00 | KDM4E (0.40) | KDM4EL3MBTL1JAK2JAK1TYK2 | |
| SCHEMBL21834207 | 0.84 | PDE4A (0.35) | KDM4EL3MBTL1JAK2JAK1TYK2 | |
| SCHEMBL21834208 | 0.84 | PDE4A (0.35) | KDM4EL3MBTL1JAK2JAK1TYK2 | |
| SCHEMBL29372186 | 0.82 | HPGD (0.39) | KDM4ENR1H4ALDH1A1TSHRHPGD | |
| SCHEMBL21876180 | 0.82 | HPGD (0.39) | KDM4ENR1H4ALDH1A1TSHRHPGD | |
| SCHEMBL21876181 | 0.82 | HPGD (0.39) | KDM4ENR1H4ALDH1A1TSHRHPGD | |
| SCHEMBL25980305 | 0.82 | HPGD (0.39) | KDM4ENR1H4ALDH1A1TSHRHPGD | |
| SCHEMBL22405862 | 0.80 | ALDH1A1 (0.43) | KDM4EL3MBTL1ALDH1A1TSHRHPGD | |
| SCHEMBL27316765 | 0.77 | CACNA1B (0.39) | KDM4EL3MBTL1MAPT | |
| SCHEMBL21876206 | 0.72 | NR1H4 (0.36) | KDM4EJAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3609888-B1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | LILLY CO ELI (US) | 2025-08-27 | — | — | EP | disclosed |
| EP-4596041-A2 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | Organovo, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| EP-3596053-B1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ORGANOVO INC (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-3596053-B1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ORGANOVO INC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20220089575-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ORGANOVO, INC. | 2022-03-24 | — | — | US | disclosed |
| US-20220056019-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. | 2022-02-24 | — | — | US | disclosed |
| US-11236071-B1 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-11236071-B1 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210300875-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ORGANOVO, INC. | 2021-09-30 | — | — | US | disclosed |
| US-20210300875-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ORGANOVO, INC. | 2021-09-30 | — | — | US | disclosed |
| US-10961198-B2 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-10961198-B2 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-10927082-B2 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-20200290973-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2020-09-17 | — | — | US | disclosed |
| US-20200131129-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. | 2020-04-30 | — | — | US | disclosed |
| US-20200131142-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. | 2020-04-30 | — | — | US | disclosed |
| US-20200131142-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. | 2020-04-30 | — | — | US | disclosed |
| US-20200131134-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2020-04-30 | — | — | US | disclosed |
| US-20200131134-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2020-04-30 | — | — | US | disclosed |
| US-20200131129-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220056019-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | KDM4E 4790/4885L3MBTL1 4422/4885JAK2 2538/4885 |
| US-20200131142-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | KDM4E 4790/4885L3MBTL1 4422/4885JAK2 2538/4885 |
| US-20200131129-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | KDM4E 4790/4885L3MBTL1 4422/4885JAK2 2538/4885 |
| US-20210300875-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | KDM4E 4790/4885L3MBTL1 4422/4885JAK2 2538/4885 |
| US-20220089575-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | KDM4E 4790/4885L3MBTL1 4422/4885JAK2 2538/4885 |
| US-20200131134-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | KDM4E 4790/4885L3MBTL1 4422/4885JAK2 2538/4885 |
| US-11236071-B1 | Farnesoid X receptor agonists and uses thereof | NR1H4, NR1H2, NR1H3 | KDM4E 4790/4885L3MBTL1 4422/4885JAK2 2538/4885 |
| US-20200290973-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | KDM4E 4790/4885L3MBTL1 4422/4885JAK2 2538/4885 |
| US-10961198-B2 | Farnesoid X receptor agonists and uses thereof | NR1H4, NR1H2, NR1H3 | KDM4E 4790/4885L3MBTL1 4422/4885JAK2 2538/4885 |
| US-10927082-B2 | Farnesoid X receptor agonists and uses thereof | NR1H4, NR1H2, NR1H3 | KDM4E 4790/4885L3MBTL1 4422/4885JAK2 2538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.